A Distinct Profile of Serum Levels of Soluble Trail and Glycated Hemoglobin in Diabetic Nephropathy and its Relation to Different Treatment Modalities

SARIKAYA M; Bisgin A; Sari F; Cerit  N; Cetinkaya R; Yalcin AD

Volume : IV, Issue : VI, June - 2014

A Distinct Profile of Serum Levels of Soluble Trail and Glycated Hemoglobin in Diabetic Nephropathy and its Relation to Different Treatment Modalities

Sarikaya M, Bisgin A, Sari F, Cerit N, Cetinkaya R, Yalcin Ad

Abstract :

Background : TNF–related apoptosis–inducing ligand(TRAIL) was originally isolated as an inducer of apoptosis and was an important component of the immune system. Diabetic nephropathy(DN) also occurs as a late complication and chronic inflammation plays a crucial role. Although it is well acknowledged that TRAIL has an important role in Type–1(T1D) and Type–2 Diabetes(T2D) development, it is unknown whether TRAIL can inversely reflect the progression of diabetes. Our aim was to investigate the possible role of serum soluble TRAIL(sTRAIL) in DN patients. Material and Methods: We examined the association between sTRAIL and HbA1C levels, BUN, creatinin and spot urine protein were evaluated as a surrogate marker of DN in three groups of T2D patients; newly diagnosed non–treated(n=22), oral anti–diabetic drug using(n=14) and insulin–treated(n=20). Results: sTRAIL level is correlated with BUN in insulin using DN patients and HbA1C % is correlated with BUN and uric acid in oral antidiabetic drug using patients. However, there was no significant change in the sTRAIL and HbA1C levels according to the nephropathy between two patient groups that were treated differentially. Conclusion: Besides the limitation of the number of patients, our results show that sTRAIL levels showed distinctive values in DN patients depending on the treatment.